Topline results from the Phase 3 Essence-TIMI 73b study provide encouraging evidence of the efficacy of olezarsen in patients with moderate hypertriglyceridaemia (fasting TG 150 mg/dL to <500 mg/dL) with or at risk of atherosclerotic cardiovascular disease (ASCVD).
Preclinical data support MAR001 safety and therapeutic potential
Results of preclinical studies with the ANGPTL4 antibody, MAR001, support its therapeutic potential and help allay safety concerns about ANGPTL4 inhibition. The results, published in eBioMedicine, show that, in cynomolgus monkeys with hypertriglyceridaemia, a single dose of MAR001 3 mg/kg sc reduced plasma TG by more than 40% from baseline within three days of dosing and led to a peak TG reduction of 58% on day 7 post-dose. MAR001 consistently lowered plasma TG by more than 40% from baseline on days 3 through 21 post-dose. There were also reductions in non-HDL-C, apoB and remnant cholesterol (RC) of 38%, 30%, and 59% respectively.
Hypertriglyceridaemia still common in CHD secondary prevention patients
One in three individuals receiving CHD secondary prevention care has hypertriglyceridaemia (HTG), despite the fact that 85% use lipid-modifying therapies, mainly statins.
Expert consensus proposes pragmatic approach to chylomicronaemia classification
Recently published guidance on the management of chylomicronaemia emphasises risk stratification and clinical criteria over strict genetic classifications to better guide treatment and reduce the risk of severe complications, including pancreatitis. The Joint Expert Clinical Consensus of the National Lipid Association (NLA) and the American Society for Preventive Cardiology (ASPC) suggests that instead of dividing individuals […]
Plozasiran shows beneficial effects on TRL particles
Plozasiran was associated with favourable changes to the number and size of triglyceride-rich lipoprotein particles (TRL-P) in the Phase 2 SHASTA-2 and MUIR studies in patients with severe hypertriglyceridaemia and mixed hyperlipidaemia, respectively.
Icosapent ethyl benefits on CV outcomes unaffected by baseline LDL-C
Among statin-treated patients with elevated TG and high cardiovascular (CV) risk, icosapent ethyl (IPE) reduced CV events irrespective of baseline LDL-C. These are the latest findings to be published from post hoc analyses of data from REDUCE-IT. Among 8175 patients with baseline LDL-C data, 7117 (87.1%) had LDL-C ≥55 mg/dL and 1058 (12.9%) had LDL-C […]
